Published in Vaccine Weekly, February 13th, 1995
On January 27, 1995, the U.S. Food and Drug Administration (FDA) Vaccines and Related Biologicals Products Committee met to discuss issues related to the varicella-zoster virus vaccine live, developed by Merck and Company Inc., White House Station, New Jersey. Merck has named the vaccine Varivax.
The Vaccines and Related Biologicals Products Committee, a group of outside experts, previously had advised the FDA to look into several issues before making a final decision on approval, indicated Monica Revelle, spokesperson for the FDA.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly